Androgen Antagonists

• 

  Subject Areas on Research

  • 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. 
  • A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer. 
  • A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • A role for the androgen receptor in the treatment of male breast cancer. 
  • ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. 
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. 
  • Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. 
  • American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. 
  • An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. 
  • Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. 
  • Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. 
  • Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. 
  • Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. 
  • Androgen deprivation therapy for prostate cancer results in significant loss of bone density. 
  • Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. 
  • Androgen deprivation therapy: further confirmation of known harms. 
  • Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 
  • Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. 
  • Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. 
  • Androgens and masculinization of genitalia in the spotted hyaena (Crocuta crocuta). 2. Effects of prenatal anti-androgens. 
  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). 
  • Antiandrogens in the treatment of priapism. 
  • Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Biochemical recurrence of prostate cancer. 
  • Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. 
  • Carcinoma of the prostate: the therapeutic dilemma. 
  • Castration-resistant prostate cancer: AUA Guideline. 
  • Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation. 
  • Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer. 
  • Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. 
  • Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 
  • Clinical phenotypes of castration-resistant prostate cancer. 
  • Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. 
  • Combination hormonal therapy: a reassessment within advanced prostate cancer. 
  • Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. 
  • Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. 
  • Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. 
  • Controversies in the treatment of prostate cancer with maximal androgen deprivation. 
  • Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. 
  • Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? 
  • Cross-sectional survey of long-term quality of life after radical perineal prostatectomy. 
  • Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. 
  • Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. 
  • Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. 
  • Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. 
  • Docetaxel for advanced prostate cancer: how early to start? 
  • Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? 
  • Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? 
  • Early prostate cancer: prevention, treatment modalities, and quality of life issues. 
  • Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. 
  • Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. 
  • Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 
  • Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation. 
  • Effects of prenatal treatment with antiandrogens on luteinizing hormone secretion and sex steroid concentrations in adult spotted hyenas, Crocuta crocuta. 
  • Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. 
  • Endocrine modulation of reproduction. 
  • Endocrine therapy in metastatic breast cancer. 
  • Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. 
  • Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. 
  • Evaluation and treatment of male and female pattern hair loss. 
  • Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. 
  • Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. 
  • Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. 
  • Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time? 
  • Exposure to naturally circulating androgens during foetal life incurs direct reproductive costs in female spotted hyenas, but is prerequisite for male mating. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. 
  • Genomic strategy for targeting therapy in castration-resistant prostate cancer. 
  • Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. 
  • High-risk prostate cancer: from definition to contemporary management. 
  • Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. 
  • Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. 
  • Hormone refractory prostate cancer: Management and advances. 
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. 
  • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. 
  • Indications and practice with androgen deprivation therapy. 
  • Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. 
  • Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. 
  • Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. 
  • Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group. 
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 
  • Is NNT AOK? 
  • Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No. 
  • Ligand-specific dynamics of the androgen receptor at its response element in living cells. 
  • Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. 
  • MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. 
  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 
  • Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. 
  • Molecular implications of the antiandrogen withdrawal syndrome. 
  • Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. 
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. 
  • NCCN clinical practice guidelines in oncology: prostate cancer. 
  • Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con. 
  • Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. 
  • Neoadjuvant hormone therapy: the Canadian trials. 
  • New drug development in metastatic prostate cancer. 
  • New drugs in prostate cancer. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Novel therapies for the treatment of advanced prostate cancer. 
  • Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. 
  • Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 
  • Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. 
  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. 
  • Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. 
  • Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. 
  • Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. 
  • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. 
  • Prostate cancer in the late 1990s: hormone refractory disease options. 
  • Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. 
  • Prostate cancer. 
  • Prostate specific antigen recurrence after definitive therapy. 
  • Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. 
  • Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. 
  • Prostatic malignancy. 
  • Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. 
  • Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. 
  • Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. 
  • Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Regulation of the macrophage population in postnatal rat testis. 
  • Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. 
  • Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. 
  • Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. 
  • Rising prostate-specific antigen after primary prostate cancer therapy. 
  • Role of androgen deprivation therapy for node-positive prostate cancer. 
  • Salvage radiation in men after prostate-specific antigen failure and the risk of death. 
  • Second-line chemotherapy for advanced hormone-refractory prostate cancer. 
  • Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. 
  • Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis. 
  • Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. 
  • Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. 
  • Steroidal modulation of steroid secretion in vitro: an experimental approach to intra-follicular regulatory mechanisms. 
  • Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). 
  • Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. 
  • Testosterone in prostate cancer: the Bethesda consensus. 
  • The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. 
  • The STAMPEDE trial and celecoxib: how to adapt? 
  • The anti-androgen combination, flutamide plus finasteride, paradoxically suppressed LH and androgen concentrations in pregnant spotted hyenas, but not in males. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. 
  • The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. 
  • The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. 
  • The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. 
  • The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer. 
  • Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Traditional approaches to androgen deprivation therapy. 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. 
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. 
  • Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. 
  • Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. 
  • What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate? 
  • [Ovarian suppression with Diane 35/50] 
• 

  Keywords of People

  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology